Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET) Meeting Abstract
| Authors: | Jhaveri, K.; Juric, D.; Yap, Y. S.; Cresta, S.; Layman, R.; Duhoux, F.; Terret, C.; De Vita, S.; Kundamal, N.; He, W.; Balbin, A.; Sheng, Q.; Crystal, A.; Curigliano, G. |
| Abstract Title: | Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET) |
| Meeting Title: | ESMO Breast Cancer Virtual Meeting 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2020 May 23-24 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-05-01 |
| Start Page: | S62 |
| Language: | English |
| ACCESSION: | WOS:000538879300120 |
| DOI: | 10.1016/j.annonc.2020.03.311 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA1 -- ESMO Breast Cancer Virtual Meeting -- MAY 23-24, 2020 -- ELECTR NETWORK -- 2 -- Source: Wos |
